Top Industry Leaders in the Parathyroid Disorders Market
Latest Parathyroid Disorders Companies Update
November 2023: The EC approved YORVIPATH® (palopegteriparatide) as a replacement medication for people with persistent hypoparathyroidism, according to an announcement by Ascendis Pharma A/S. If you're using parathyroid hormone (PTH 1-34) prodrug, you should take it once a day. Ascendis is planning to commercialize YORVIPATH in Germany in January 2024, marking its first launch in the European Union (EU). There are major issues with health and quality of life for any patient dealing with chronic hypoparathyroidism. These individuals require innovative approaches to treatment that overcome the limitations and hazards of current standard medication, which mostly comprises of oral calcium and active vitamin D, in order to address the root cause of their ailment. For the treatment of individuals with persistent hypoparathyroidism, TransCon PTH, branded as YORVIPATH in the European Union, is a parathyroid hormone (PTH) replacement medication.
March 2022: The formation of Pathalys Pharma, Inc. was announced in March 2022. The company is a private, late-stage biopharma focused on developing and commercializing various best-in-class therapies for patients with chronic kidney disease (CKD). Initial seed financing for this formation came from DaVita Venture Group, which is a part of DaVita Inc., and Catalys Pacific. With the acquisition of upacicalcet, a unique clinical-stage asset, Pathalys gained exclusive rights to develop and market the medicine globally, except Japan and Asia, thanks to a license given by EA Pharma. The business is thrilled about the chance to collaborate with DaVita, a prominent player in the kidney care industry, to bring new treatments for patients with chronic kidney disease (CKD), starting with upacicalcet.List of Parathyroid Disorders Key companies in the market
- Bayer Healthcare
- Becton
- Dickinson and Company
- Eli Lilly, Ethicon, Inc.
- Genentech
- Medtronic
- Merck
- Mylan Laboratories
- Novartis
- Novo Nordisk
- Pfizer
- Roche
- Smith & Nephew plc
- Stryker
- Teva Pharmaceutical Industries Ltd.
- Zimmer Biomet Holdings, Inc.